Editorial review
Educational content is reviewed for source quality, clinical boundaries, and readability. It is not medical advice; confirm care decisions with a licensed clinician.
Generic ketamine vs Spravato is the choice most patients face once they decide to explore ketamine-based treatment for depression, and the two options differ mainly in regulatory status, treatment setting, and cost, not necessarily in raw effectiveness. Generic ketamine is a racemic formulation prescribed off-label by physicians for conditions like treatment-resistant depression, anxiety, and PTSD. Spravato (esketamine) is an FDA-approved nasal spray built from a single, more potent piece of the ketamine molecule, and it is available only at certified facilities under a federal risk management program.
Both options act on the same receptor system in the brain that appears to drive ketamine's rapid antidepressant effect, but how each is regulated, delivered, and paid for can matter as much to a patient's decision as the underlying chemistry. This guide compares generic ketamine and Spravato across FDA status, effectiveness, treatment experience, cost, access, and safety, so you can bring specific questions to your provider. For related background, see our comparison of ketamine and esketamine.
Quick Answer
Generic ketamine, prescribed off-label as a racemic IV, intramuscular, oral, or sublingual formulation, and Spravato (esketamine), an FDA-approved nasal spray, differ mainly in regulatory status, treatment setting, and insurance coverage rather than in overall effectiveness. Spravato must be given at a certified clinic under a federal risk management program, with two hours of monitored observation after each dose, while generic ketamine can be administered in more settings, including at home for some formulations. Insurance covers Spravato more often than generic ketamine, which can make it cheaper out-of-pocket despite a higher list price, while self-pay patients, especially those using sublingual ketamine, often find generic ketamine more affordable.
The Chemistry: Racemic Ketamine vs. Esketamine
Generic ketamine is a racemic compound, meaning each dose contains equal parts of two mirror-image molecules called S-ketamine and R-ketamine. Esketamine is the S-enantiomer of ketamine isolated on its own, and it is the active ingredient in Spravato. The N-methyl-D-aspartate (NMDA) receptor is a brain receptor involved in mood regulation and pain signaling that both ketamine and esketamine block, a mechanism researchers believe drives ketamine's rapid antidepressant response.
S-ketamine binds to NMDA receptors with roughly four times the affinity of R-ketamine, making it the more potent of the two enantiomers on that specific measure. Some researchers have proposed that R-ketamine contributes separate therapeutic effects through different receptor pathways, which would give racemic ketamine a broader mechanism of action than esketamine alone. That theory remains under active study, and its clinical significance has not been established.
FDA Approval Status
Spravato
The FDA approved Spravato in March 2019 for treatment-resistant depression in adults, and later expanded that approval to include major depressive disorder with acute suicidal ideation or behavior, according to the FDA's approval announcement. That approval requires Spravato to be dispensed under a Risk Evaluation and Mitigation Strategy (REMS), an FDA program that places extra prescribing, dispensing, and monitoring restrictions on medications with a meaningful safety risk. Under Spravato's REMS requirements:
- Dosing follows a standardized protocol based on phase 3 clinical trial data
- Administration is limited to certified healthcare facilities
- Patients must be monitored for at least two hours after each dose
- There is a defined regulatory pathway insurers can use to evaluate coverage
The FDA's REMS database lists the full monitoring requirements certified facilities must follow.
Generic Ketamine
Generic ketamine is FDA-approved only as an anesthetic. Its use for depression, anxiety, PTSD, and other psychiatric conditions is off-label, meaning physicians are prescribing it for a purpose outside its formal FDA indication. Off-label prescribing is legal and common in medicine, accounting for roughly 20 percent of prescriptions written in the United States, but it also means:
- There is no FDA-mandated treatment protocol
- Dosing and scheduling vary by provider
- Insurance coverage is harder to obtain
- The regulatory framework around delivery and monitoring is less defined
Effectiveness
Generic Ketamine
Racemic IV ketamine has been studied in hundreds of clinical trials since a foundational 2006 trial published in Archives of General Psychiatry found rapid antidepressant effects in patients with treatment-resistant depression. Response rates across the accumulated evidence base consistently range from 60 to 70 percent for treatment-resistant depression. That evidence spans more than two decades and multiple routes of administration, including IV, IM, sublingual, and oral. Many clinicians consider IV racemic ketamine to have the strongest overall evidence base of any ketamine-based depression treatment, in part because of that longer track record. For more on how response can change over time, see our guide to NMDA antagonist discontinuation rates.
Spravato
Spravato's FDA approval rested on multiple phase 3 clinical trials that found statistically significant improvement over placebo for treatment-resistant depression. Some clinicians have noted that the effect sizes in those phase 3 trials were more modest than the effect sizes reported in earlier racemic ketamine studies. Spravato has also shown efficacy in reducing suicidal ideation in acute settings, which was the basis for its second FDA indication.
Head-to-Head Comparisons
Direct comparisons between racemic ketamine and esketamine remain limited but are growing. A 2021 systematic review and meta-analysis in the Journal of Affective Disorders found broadly comparable efficacy between the two, with some individual studies favoring racemic IV ketamine and others showing no significant difference. A 2024 review in Molecular Psychiatry reached a similar conclusion. The question is unlikely to be settled without larger, well-designed head-to-head trials.
Administration and Treatment Experience
Generic Ketamine
Generic ketamine can be delivered through several routes, each with its own setting and schedule:
- IV infusion: administered in a clinic, 40 to 60 minutes plus recovery time, typically six sessions over two to three weeks followed by maintenance dosing
- IM injection: administered in a clinic, 45 to 75 minutes total, frequency varies by provider protocol
- Sublingual: taken at home or in a clinic, 60 to 90 minutes, usually one to three times weekly
- Oral: taken at home or in a clinic, 60 to 120 minutes, frequency varies by provider protocol
Generic ketamine offers the most flexibility in how treatment is delivered, since providers can choose the route, dose, and schedule that fits each patient. See our comparison of oral and sublingual ketamine for more on how those two routes differ, and our guide to how long a ketamine session lasts for a fuller session-by-session breakdown.
Spravato
Spravato is self-administered as a nasal spray at a certified healthcare facility under clinical supervision, then followed by a mandatory two-hour observation period. Treatment occurs twice weekly for the first month, weekly for the second month, then weekly or biweekly during maintenance. A typical visit includes vital sign assessment, self-administration of the spray under supervision, two hours of monitoring for blood pressure and mental status, and clearance to leave with arranged transportation.
Cost and Insurance
Generic Ketamine
Per-session cost for IV ketamine typically runs $400 to $800, while sublingual programs run roughly $150 to $400 per month. Insurance rarely covers generic ketamine because of its off-label status, so most patients pay out-of-pocket, though HSA and FSA funds can usually be applied. Some clinics offer payment plans to help spread out the cost.
Spravato
Spravato's list price runs $590 to $885 per session before insurance. Because it has FDA approval and a defined regulatory pathway, insurance more often covers it with prior authorization, and typical copays with insurance range from $0 to $250 per session. Janssen, the manufacturer, offers a patient assistance program called CarePath. Without insurance, Spravato typically costs $600 to $900 per session.
This creates a reversal worth understanding: Spravato has a higher list price than most generic ketamine treatment, but insurance coverage can make it less expensive out-of-pocket for patients with qualifying plans. Patients without insurance, particularly those considering sublingual programs, typically find generic ketamine the more affordable option.
Access and Availability
Generic ketamine clinics operate in most metropolitan areas, and telehealth sublingual programs are available in many states. Because generic ketamine is not restricted by a REMS program, providers have more flexibility in how and where they deliver it, including at-home sublingual and oral options. That flexibility has also drawn regulatory scrutiny of some online ketamine sellers; see our coverage of the federal investigation into online ketamine sellers and at-home use for more on that oversight.
Spravato can only be administered at facilities certified under its REMS program. The number of certified facilities has grown substantially since 2019, but availability can still be limited in rural areas, and the mandatory two-hour observation window adds a practical time commitment that generic ketamine's at-home options do not require. If you're weighing an at-home sublingual program specifically, our guide to at-home sublingual ketamine for anxiety covers what to expect from that setting.
Safety Considerations
Racemic ketamine and esketamine share a similar side effect profile, including dissociation, dizziness, sedation, nausea, increased blood pressure, and headache. Spravato's REMS program mandates specific monitoring protocols, including vital sign checks and the two-hour observation period. Generic ketamine clinics set their own safety protocols, and the rigor of that monitoring varies by provider. In practice, the quality of safety oversight depends more on the individual clinic or prescriber than on which formulation you choose. Our guide to evaluating provider credentials and our overview of ketamine side effects and safety can help you assess a specific clinic before starting treatment.
Choose Generic Ketamine If
- You prefer IV administration for its higher bioavailability
- You want more flexibility in dosing and treatment schedule
- You do not have insurance that covers Spravato
- You prefer at-home sublingual treatment for convenience and cost
- Your provider recommends racemic ketamine based on your specific presentation
Choose Spravato If
- You have insurance that covers Spravato with a manageable copay
- You value the standardized FDA-approved protocol and REMS safety oversight
- You prefer a nasal spray to IV access or sublingual dosing
- Your insurance requires you to try the FDA-approved option first
- You want the assurance of FDA regulatory oversight
Questions to Ask Before Choosing
- Does my insurance plan cover Spravato, and what would my copay be after prior authorization?
- What out-of-pocket cost should I expect for generic ketamine at this clinic, and are payment plans available?
- Which administration route (IV, IM, sublingual, oral, or nasal spray) fits my medical history and schedule?
- What safety monitoring does this clinic provide during and after each session?
- How many sessions are recommended before we evaluate whether treatment is working?
- Is this facility REMS-certified if I'm considering Spravato, and how far is it from home?
Key Takeaway
Generic ketamine and Spravato appear broadly comparable in effectiveness for treatment-resistant depression. The decision often comes down to insurance coverage, administration setting, and how much regulatory oversight and flexibility matter to you, not which drug works better.
Read More Treatment Comparisons
Compare more ketamine treatment options, costs, and care models to find the right fit for your situation.
Frequently Asked Questions
Yes, some patients start with one and switch to the other based on cost, insurance changes, or response. Talk with your prescriber before switching, since dosing and monitoring protocols differ between the two.
Not necessarily. Esketamine has higher NMDA receptor binding affinity than R-ketamine alone, but racemic ketamine's studied dose ranges and delivery routes produce broadly comparable response rates in the evidence available so far.
It's uncommon, since psychiatric use of generic ketamine is off-label. Some clinics document sessions under different billing codes that may be partially reimbursed, but coverage should be confirmed with your insurer before treatment, not assumed.
The FDA's REMS program requires certified administration because of the risk of sedation, dissociation, and blood pressure changes immediately after dosing, and because of the drug's potential for misuse. The two-hour observation window lets clinical staff monitor for those effects before a patient leaves.
Verdict
Generic ketamine offers greater flexibility in dosing and administration routes, often at a lower out-of-pocket cost, and has a longer clinical track record in off-label use. Spravato's FDA approval provides a standardized protocol, regulatory oversight, and a clearer pathway to insurance coverage, though actual insurance costs vary. Neither is definitively superior in effectiveness; the best choice depends on your insurance situation, access to certified facilities, and provider recommendation.
Share
Related Reading
Need help or want to reach readers?
Have a correction, provider question, or advertising inquiry? Reach the editorial team.